Jean-Michel Quinot
CEO, Nordic Pharma
Jean-Michel Quinot brings more than 35 years of pharmaceutical industry experience. He joined Nordic Pharma in 2019 from Amring International where he served as CEO during the five previous years. Prior to that, Jean-Michel held positions of increasing responsibility in General Management at Bristol-Myers Squibb, successively in charge of Austria, Poland and then Africa.
Prior to joining Bristol Myers Squibb, Jean-Michel spent fifteen years with Hoechst Marion Roussel (now part of Sanofi) in a number of leadership positions, mainly in Finance and General Management, in Europe and in the US. Jean-Michel holds an Electro-chemical engineer degree from Grenoble Polytechnic school, an MBA from HEC Paris and a Strategic Marketing degree from Columbia University.
Daniel Carbery
CEO, Amring USA
President and CEO of Amring Pharmaceuticals Inc. in USA with 5+ years building Amring from startup in the USA and a total of 19 years in the pharmaceutical industry. Daniel was graduated with a Bachelors degree in chemical engineering from Princeton University, with an MBA from Rutgers University in New Jersey, and from the Officers Basic Course in the U.S. Army Field Artillery School in Oklahoma. He has 38 years of experience starting, restructuring, acquiring and improving businesses in the pharmaceutical, consumer health, food and consumer products, environmental management, and strategic consulting fields. Daniel has progressed through large, small, and turnaround companies including Endo Pharmaceuticals, Procter and Gamble, Nabisco, KPMG, SmithKline Beecham, Axcentria, and the US Army.
Kenneth Stokholm
CEO, Pharma Services
CEO of Pharmaceutical Services group at Sever Life Sciences, Kenneth brings 25 years of pharmaceutical industry experience. Kenneth joined QPharma as CEO in 2009 and has served in several roles at Nordic Group, including SVP of Technical operations and Strategic Development. Prior to this, he spent eight years in several international positions with Xellia pharmaceuticals, incl GM China, and five years in different technical roles with Novo Nordisk. Kenneth holds an MSc in chemical engineering from the technical university of Denmark (DTU) and an executive MBA from HEC in Paris.
Orest Ibragimov
CEO, Izvarino Pharma
General manager of Izvarino Pharma LLC from 2010 to the present. General manager of Nanopharma Development from 2016 to the present. In the Russian pharmaceutical business since 1996. Present activities together with the Russian team introduced to the Russian market the company Astellas Pharma and carried out the development of the Russian company Alium. Medical Doctor, pharmacologist (PhD), DBA (Higher School of Economics, Moscow), Stanford graduate school of business (Stanford, CA).
Aernout de Bruijne
Director of Finance & Operations Planning
Director of Finance & Operating Planning working in the pharmaceutical industry over nine years and prior to this held several international positions in the software industry, over a ten year period for Informatica, a US public IT company taken private, as well as the private IT company Information Builders, overseeing international finance functions within Europe and Australia. Holding a bachelor degree in business economics and a MBA from NCOI.
Shahed Ashraf
Group Human Resources & Corporate Communications Officer
Shahed has over 30 years of in HR experience in a wide range of industries holding various Country , Regional, European and Global HR roles. Some of the Companies he has worked for include Wyeth Pharmaceuticals, Novartis Pharmaceuticals, General Electric and Ferring Pharmaceuticals.
He is extremely passionate about Diversity & Inclusion having held the position of Global Director, Diversity & Inclusion prior to joining SEVER.
Shahed holds a Master of Arts in Strategic Human Resource Management from Kingston University, London.